Share

New Phase 2 Trial for Congenital Adrenal Hyperplasia Drug Initiated

A new phase 2 clinical trial to test the efficacy of a new drug to treat the rare inherited disorder congenital adrenal hyperplasia (CAH) will soon be underway. CAH is caused by a steroidogenic enzyme deficiency that is characterized by overgrowth of the adrenal glands, adrenal insufficiency, and androgen excess. The most frequent form of...
Share

Adrenal Cancer: Hope on the Horizon

With an estimated worldwide occurrence of only 200 patients each year, adrenal cancer is so rare that most endocrinologists will never have to deal with it. While this paucity of cases makes drug trials difficult, potential new treatments are generating hope. Of all the cancers that strike the body’s endocrine system, adrenal cortical carcinoma (ACC)...
Share

Eureka! Top Endocrinology Discoveries of 2015: A Year in Review

eureka Endocrine News has compiled the leading breakthroughs in endocrine research over the course of the past year with the help from 11 editors from Endocrine Reviews. From genetic research to new thyroid cancer drugs, amazing progress is being made in the field of endocrinology. Each year brings us a little closer to solving complex endocrine...
Share

Heir Apparent: A Multi-Faceted Look at One of the Most Common Inherited Metabolic Disorders, Congenital Adrenal Hyperplasia

Basic Researcher Nils Krone, MD, FRCPCH, Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Birmingham, UK Clinical Researcher Richard J. Auchus, MD, PhD, Professor and Endocrinology Fellowship Program Director Division of Metabolism, Endocrinology, and Diabetes; Department of Internal Medicine, University of Michigan, Ann Arbor, Mich. Clinical Practitioner Nicole Reisch, MD, Head of CAH outpatient...